Warning letter
Lovelace Biomedical Research Institute: warning letter of Oct 6, 2026
FDA warning letter 725136 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 725136 |
|---|---|
| Company | Lovelace Biomedical Research Institute |
| Subject | Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies |
| Issue date | Oct 6, 2026 |
| Posted date | Oct 13, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 58.35(b)(6), 58 |
| Inspection city | Albuquerque |
| Inspection ZIP | 87185 |
| Inspection start date | Apr 7, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: